to promote the development, harmonization and use of standards for
clinical trials of medicines for children; to revise and regularly update the
Model List of Essential Medicines in order to include missing essential
medicines for children, using evidence-based clinical guidelines; and to
promote application of such guidelines by Member States and international
financing bodies, with initial focus on treatments for HIV/AIDS, tuberculosis,
malaria and chronic diseases;

to ensure that all relevant WHO programmes, including but not limited to
that on essential medicines, contribute to making safe and effective medicines
as widely available for children as for adults;

to promote the development of international norms and standards for
quality and safety of formulations for children, and of the regulatory capacity
to apply them;

to make available evidence-based treatment guidelines and independent
information on dosage and safety aspects of essential medicines for children,
progressively to cover all medicines for children, and to work with Member
States in order to implement such guidelines;

to collaborate with governments, other organizations of the United
Nations system, including WTO and WIPO, donor agencies, nongovernmental
organizations and the pharmaceutical industry in order to encourage fair trade
in safe and effective medicines for children and adequate financing for
securing better access to medicines for children;

to report to the Sixty-second World Health Assembly, and subsequently as
appropriate, through the Executive Board, on progress achieved, problems
encountered and specific actions needed to further promote better access to
medicines for children.